Wells Fargo
ENSC icon

Wells Fargo’s Ensysce Biosciences ENSC Stock Holding History

Wells Fargo’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2
Closed -$20 – 7055
2024
Q1 		$20 Hold
2
– – ﹤0.01% 7111
2023
Q4 		$25 Buy
2
+1
+100% +$16 ﹤0.01% 7135
2023
Q3 		$29 Hold
1
– – ﹤0.01% 7080
2023
Q2 		$18 Buy
+1
New +$45 ﹤0.01% 7321
2023
Q1 		– Hold
0
– – – 7319
2022
Q4 		– Hold
0
– – – 7404
2022
Q3 		– Hold
0
– – – 6818
2022
Q2 		– Hold
0
– – – 6966
2022
Q1 		– Hold
0
– – – 7232
2021
Q4 		– Hold
0
– – – 7350
2021
Q3 		– Hold
0
– – – 7080

Other funds holding ENSC

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo's ENSC Position: Q2 2024 in Review

Wells Fargo sold out of Ensysce Biosciences (ENSC) in Q2 2024, closing a stake of 2 shares — an estimated $20 sold.

Wells Fargo first reported a position in ENSC in Q2 2023 and held it in 4 quarters. The position peaked at $29 in Q3 2023. 11 funds tracked by Wall St. Rank hold ENSC as of Q2 2024.

  • Wells Fargo reported no remaining Ensysce Biosciences position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 2 Ensysce Biosciences shares in Q2 2024, an estimated $20.
  • Wells Fargo first reported a position in Ensysce Biosciences in Q2 2023 and held it in 4 quarters.
  • Wells Fargo's Ensysce Biosciences position peaked at $29 in Q3 2023.
  • 11 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.